Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies

British Journal of Haematology

Volumn 158, Issue 3, 2012, Pages 323-335

  Scully, Marie ^a   Hunt, Beverley J ^b   Benjamin, Sylvia ^c   Liesner, Ri ^d   Rose, Peter ^e   Peyvandi, Flora ^f   Cheung, Betty ^d   Machin, Samuel J ^g  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^c OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

^f UNIVERSITY OF MILAN   (Italy)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Guidelines; Thrombotic microangiopathy; Thrombotic thrombocytopenic purpura

Indexed keywords

ACETYLSALICYLIC ACID; ANTIRETROVIRUS AGENT; ANTITHROMBOCYTIC AGENT; BLEOMYCIN; BLOOD CLOTTING FACTOR 8; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DIPYRIDAMOLE; ESTROGEN DERIVATIVE; FOLIC ACID; FRESH FROZEN PLASMA; GEMCITABINE; LOW MOLECULAR WEIGHT HEPARIN; METHYLPREDNISOLONE; MITOMYCIN C; ORAL CONTRACEPTIVE AGENT; PEGINTERFERON; QUININE; RITUXIMAB; SIMVASTATIN; TACROLIMUS; TICLOPIDINE; TRIMETHOPRIM; VINCRISTINE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ALLERGIC REACTION; ANAPHYLAXIS; CENTRAL VENOUS CATHETER THROMBOSIS; CLINICAL FEATURE; DIAGNOSTIC TEST; DISEASE CLASSIFICATION; EMBASE; EVIDENCE BASED MEDICINE; HEALTH CARE PERSONNEL; HEMOLYTIC UREMIC SYNDROME; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; MEDICAL EXPERT; MEDICAL SOCIETY; MEDLINE; MICROANGIOPATHY; NOTE; PATHOGENESIS; PLASMA TRANSFUSION; PLASMAPHERESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SPLENECTOMY; THROMBOCYTOPENIA; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT;

DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MALE; PREGNANCY; PURPURA, THROMBOTIC THROMBOCYTOPENIC; THROMBOTIC MICROANGIOPATHIES;

EID: 84863841323     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2012.09167.x     Document Type: Note

References (106)

1. Al-Akash, S.I., Almond, P.S., Savell, Jr, V.H., Gharaybeh, S.I. & Hogue, C. (2011) Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutation. Pediatric Nephrology (Berlin, Germany), 26, 613-619.
2. Allford, S.L., Harrison, P., Lawrie, A.S., Liesner, R., MacKie, I.J. & Machin, S.J. (2000) Von Willebrand factor-cleaving protease activity in congenital thrombotic thrombocytopenic purpura. British Journal of Haematology, 111, 1215-1222.
3. Allford, S.L., Hunt, B.J., Rose, P. & Machin, S.J. (2003) Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias. British Journal of Haematology, 120, 556-573.
4. Ambrose, A., Welham, R.T. & Cefalo, R.C. (1985) Thrombotic thrombocytopenic purpura in early pregnancy. Obstetrics and Gynecology, 66, 267-272.
5. Ariceta, G., Besbas, N., Johnson, S., Karpman, D., Landau, D., Licht, C., Loirat, C., Pecoraro, C., Taylor, C.M., Van de Kar, N., Vandewalle, J. & Zimmerhackl, L.B. (2009) Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatric Nephrology (Berlin, Germany), 24, 687-696.
6. Balduini, C.L., Gugliotta, L., Luppi, M., Laurenti, L., Klersy, C., Pieresca, C., Quintini, G., Iuliano, F., Re, R., Spedini, P., Vianelli, N., Zaccaria, A., Pogliani, E.M., Musso, R., Bobbio, P.E., Quarta, G., Galieni, P., Fragasso, A., Casella, G., Noris, P. & Ascari, E. (2010) High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: a randomized study. Annals of Hematology, 89, 591-596.
7. Bandarenko, N. & Brecher, M.E. (1998) United States Thrombotic Thrombocytopenic Purpura Apheresis Study Group (US TTP ASG): multicenter survey and retrospective analysis of current efficacy of therapeutic plasma exchange. Journal of Clinical Apheresis, 13, 133-141.
8. Bayik, M.M., Akoglu, T., Tuglular, T.F., Akoglu, E., Tezal, M., Ulutin, O. & Lawrence, R. (1993) Treatment of thrombotic thrombocytopenic purpura with defibrotid. American Journal of Hematology, 43, 74-75.
9. Bianchi, V., Robles, R., Alberio, L., Furlan, M. & Lammle, B. (2002) Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood, 100, 710-713.
10. Bobbio-Pallavicini, E., Gugliotta, L., Centurioni, R., Porta, C., Vianelli, N., Billio, A., Tacconi, F. & Ascari, E. (1997) Antiplatelet agents in thrombotic thrombocytopenic purpura (TTP). Results of a randomized multicenter trial by the Italian Cooperative Group for TTP. Haematologica, 82, 429-435.
11. Bohm, M., Betz, C., Miesbach, W., Krause, M., von Auer, C., Geiger, H. & Scharrer, I. (2005) The course of ADAMTS-13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exchange and vincristine. British Journal of Haematology, 129, 644-652.
12. Bresin, E., Gastoldi, S., Daina, E., Belotti, D., Pogliani, E., Perseghin, P., Scalzulli, P.R., Paolini, R., Marceno, R., Remuzzi, G. & Galbusera, M. (2009) Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies. Thrombosis and Haemostasis, 101, 233-238.
13. Brunskill, S.J., Tusold, A., Benjamin, S., Stanworth, S.J. & Murphy, M.F. (2007) A systematic review of randomized controlled trials for plasma exchange in the treatment of thrombotic thrombocytopenic purpura. Transfusion Medicine (Oxford, England), 17, 17-35.
14. Cataland, S.R., Jin, M., Ferketich, A.K., Kennedy, M.S., Kraut, E.H., George, J.N. & Wu, H.M. (2007a) An evaluation of cyclosporin and corticosteroids individually as adjuncts to plasma exchange in the treatment of thrombotic thrombocytopenic purpura. British Journal of Haematology, 136, 146-149.
15. Cataland, S.R., Jin, M., Lin, S., Kennedy, M.S., Kraut, E.H., George, J.N. & Wu, H.M. (2007b) Cyclosporin and plasma exchange in thrombotic thrombocytopenic purpura: long-term follow-up with serial analysis of ADAMTS13 activity. British Journal of Haematology, 139, 486-493.
16. Chakravarty, E.F., Murray, E.R., Kelman, A. & Farmer, P. (2011) Pregnancy outcomes after maternal exposure to rituximab. Blood, 117, 1499-1506.
17. Coppo, P., Wolf, M., Veyradier, A., Bussel, A., Malot, S., Millot, G.A., Daubin, C., Bordessoule, D., Pene, F., Mira, J.P., Heshmati, F., Maury, E., Guidet, B., Boulanger, E., Galicier, L., Parquet, N., Vernant, J.P., Rondeau, E., Azoulay, E. & Schlemmer, B. (2006) Prognostic value of inhibitory anti-ADAMTS13 antibodies in adult-acquired thrombotic thrombocytopenic purpura. British Journal of Haematology, 132, 66-74.
18. Dervenoulas, J., Tsirigotis, P., Bollas, G., Pappa, V., Xiros, N., Economopoulos, T., Pappa, M., Mellou, S., Kostourou, A., Papageorgiou, E. & Raptis, S.A. (2000) Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS): treatment outcome, relapses, prognostic factors. A single-center experience of 48 cases. Annals of Hematology, 79, 66-72.
19. Deutsch, M., Manesis, E.K., Hadziyannis, E., Vassilopoulos, D. & Archimandritis, A.J. (2007) Thrombotic thrombocytopenic purpura with fatal outcome in a patient with chronic hepatitis C treated with pegylated interferon-a/2b. Scandinavian Journal of Gastroenterology, 42, 408-409.
20. Ducloy-Bouthors, A.S., Caron, C., Subtil, D., Provot, F., Tournoys, A., Wibau, B. & Krivosic-Horber, R. (2003) Thrombotic thrombocytopenic purpura: medical and biological monitoring of six pregnancies. European Journal of Obstetrics, Gynecology, and Reproductive Biology, 111, 146-152.
21. Fakhouri, F., Vernant, J.P., Veyradier, A., Wolf, M., Kaplanski, G., Binaut, R., Rieger, M., Scheiflinger, F., Poullin, P., Deroure, B., Delarue, R., Lesavre, P., Vanhille, P., Hermine, O., Remuzzi, G. & Grunfeld, J.P. (2005) Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. Blood, 106, 1932-1937.
22. Ferrari, S., Scheiflinger, F., Rieger, M., Mudde, G., Wolf, M., Coppo, P., Girma, J.P., Azoulay, E., Brun-Buisson, C., Fakhouri, F., Mira, J.P., Oksenhendler, E., Poullin, P., Rondeau, E., Schleinitz, N., Schlemmer, B., Teboul, J.L., Vanhille, P., Vernant, J.P., Meyer, D. & Veyradier, A. (2007) Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity. Blood, 109, 2815-2822.
23. Fontana, S., Gerritsen, H.E., Kremer, H.J., Furlan, M. & Lammle, B. (2001) Microangiopathic haemolytic anaemia in metastasizing malignant tumours is not associated with a severe deficiency of the von Willebrand factor-cleaving protease. British Journal of Haematology, 113, 100-102.
24. Fujikawa, K., Suzuki, H., McMullen, B. & Chung, D. (2001) Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood, 98, 1662-1666.
25. Fujimura, Y., Matsumoto, M., Kokame, K., Isonishi, A., Soejima, K., Akiyama, N., Tomiyama, J., Natori, K., Kuranishi, Y., Imamura, Y., Inoue, N., Higasa, S., Seike, M., Kozuka, T., Hara, M., Wada, H., Murata, M., Ikeda, Y., Miyata, T. & George, J.N. (2009) Pregnancy-induced thrombocytopenia and TTP, and the risk of fetal death, in Upshaw-Schulman syndrome: a series of 15 pregnancies in 9 genotyped patients. British Journal of Haematology, 144, 742-754.
26. Fujimura, Y., Matsumoto, M., Isonishi, A., Yagi, H., Kokame, K., Soejima, K., Murata, M. & Miyata, T. (2011) Natural history of Upshaw-Schulman syndrome based on ADAMTS13 gene analysis in Japan. Journal of Thrombosis and Haemostasis, 9(Suppl 1), 283-301.
27. Furlan, M., Robles, R., Solenthaler, M., Wassmer, M., Sandoz, P. & Lammle, B. (1997) Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood, 89, 3097-3103.
28. Furlan, M., Robles, R., Solenthaler, M. & Lammle, B. (1998a) Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura. Blood, 91, 2839-2846.
29. Furlan, M., Robles, R., Galbusera, M., Remuzzi, G., Kyrle, P.A., Brenner, B., Krause, M., Scharrer, I., Aumann, V., Mittler, U., Solenthaler, M. & Lammle, B. (1998b) von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. New England Journal of Medicine, 339, 1578-1584.
30. Furlan, M., Robles, R., Morselli, B., Sandoz, P. & Lammle, B. (1999) Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura. Thrombosis and Haemostasis, 81, 8-13.
31. Galbusera, M., Noris, M. & Remuzzi, G. (2006) Thrombotic thrombocytopenic purpura-then and now. Seminars in Thrombosis and Hemostasis, 32, 81-89.
32. Gami, A.S., Hayman, S.R., Grande, J.P. & Garovic, V.D. (2005) Incidence and prognosis of acute heart failure in the thrombotic microangiopathies. American Journal of Medicine, 118, 544-547.
33. George, J.N., Li, X., McMinn, J.R., Terrell, D.R., Vesely, S.K. & Selby, G.B. (2004) Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma. Transfusion, 44, 294-304.
34. Gervasoni, C., Ridolfo, A.L., Vaccarezza, M., Parravicini, C., Vago, L., Adorni, F., Cappelletti, A., d'Arminio, M.A. & Galli, M. (2002) Thrombotic microangiopathy in patients with acquired immunodeficiency syndrome before and during the era of introduction of highly active antiretroviral therapy. Clinical Infectious Diseases, 35, 1534-1540.
35. Hart, D., Sayer, R., Miller, R., Edwards, S., Kelly, A., Baglin, T., Hunt, B., Benjamin, S., Patel, R., Machin, S. & Scully, M. (2011) Human immunodeficiency virus associated thrombotic thrombocytopenic purpura-favourable outcome with plasma exchange and prompt initiation of highly active antiretroviral therapy. British Journal of Haematology, 153, 515-519.
36. Hebert, P.C., Wells, G., Blajchman, M.A., Marshall, J., Martin, C., Pagliarello, G., Tweeddale, M., Schweitzer, I. & Yetisir, E. (1999) A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. New England Journal of Medicine, 340, 409-417.
37. Heidel, F., Lipka, D.B., von Auer, C., Huber, C., Scharrer, I. & Hess, G. (2007) Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia. Thrombosis and Haemostasis, 97, 228-233.
38. Hughes, C., McEwan, J.R., Longair, I., Hughes, S., Cohen, H., Machin, S. & Scully, M. (2009) Cardiac involvement in acute thrombotic thrombocytopenic purpura: association with troponin T and IgG antibodies to ADAMTS 13. Journal of Thrombosis and Haemostasis, 7, 529-536.
39. Hull, M.J. & Eichbaum, Q.G. (2006) Efficacy of rituximab and concurrent plasma exchange in the treatment of thrombotic thrombocytopenic purpura. Clinical Advances in Hematology & Oncology, 4, 210-214.
40. Kahwash, E. & Lockwood, W.B. (2004) Twice daily plasma exchange in refractory thrombotic thrombocytopenic purpura. Therapeutic Apheresis and Dialysis, 8, 254-257.
41. Kappers-Klunne, M.C., Wijermans, P., Fijnheer, R., Croockewit, A.J., van der, H.B., de Wolf, J.T., Lowenberg, B. & Brand, A. (2005) Splenectomy for the treatment of thrombotic thrombocytopenic purpura. British Journal of Haematology, 130, 768-776.
42. Kavanagh, D. & Goodship, T.H. (2010) Atypical hemolytic uremic syndrome. Current Opinion in Hematology, 17, 432-438.
43. Kim, J.J., Goodship, T.H., Tizard, J. & Inward, C. (2011) Plasma therapy for atypical haemolytic uraemic syndrome associated with heterozygous factor H mutations. Pediatric Nephrology (Berlin, Germany), 26, 2073-2076.
44. Koduri, P.R. (1998) Simvastatin and thrombotic thrombocytopenic purpura. Lancet, 352, 2020.
45. Kwaan, H.C. & Gordon, L.I. (2001) Thrombotic microangiopathy in the cancer patient. Acta Haematologica, 106, 52-56.
46. de la Rubia, J., Arriaga, F., Linares, D., Larrea, L., Carpio, N., Marty, M.L. & Sanz, M.A. (2001) Role of methylene blue-treated or fresh-frozen plasma in the response to plasma exchange in patients with thrombotic thrombocytopenic purpura. British Journal of Haematology, 114, 721-723.
47. Lapeyraque, A.L., Malina, M., Fremeaux-Bacchi, V., Boppel, T., Kirschfink, M., Oualha, M., Proulx, F., Clermont, M.J., Le, D.F., Niaudet, P. & Schaefer, F. (2011) Eculizumab in severe Shiga-toxin-associated HUS. New England Journal of Medicine, 364, 2561-2563.
48. Levy, G.G., Nichols, W.C., Lian, E.C., Foroud, T., McClintick, J.N., McGee, B.M., Yang, A.Y., Siemieniak, D.R., Stark, K.R., Gruppo, R., Sarode, R., Shurin, S.B., Chandrasekaran, V., Stabler, S.P., Sabio, H., Bouhassira, E.E., Upshaw, Jr, J.D., Ginsburg, D. & Tsai, H.M. (2001) Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature, 413, 488-494.
49. Loirat, C., Veyradier, A., Girma, J.P., Ribba, A.S. & Meyer, D. (2006) Thrombotic thrombocytopenic purpura associated with von Willebrand factor-cleaving protease (ADAMTS13) deficiency in children. Seminars in Thrombosis and Hemostasis, 32, 90-97.
50. Loof, A.H., van Vliet, H.H. & Kappers-Klunne, M.C. (2001) Low activity of von Willebrand factor-cleaving protease is not restricted to patients suffering from thrombotic thrombocytopenic purpura. British Journal of Haematology, 112, 1087-1088.
51. Malak, S., Wolf, M., Millot, G.A., Mariotte, E., Veyradier, A., Meynard, J.L., Korach, J.M., Malot, S., Bussel, A., Azoulay, E., Boulanger, E., Galicier, L., Devaux, E., Eschwege, V., Gallien, S., Adrie, C., Schlemmer, B., Rondeau, E. & Coppo, P. (2008) Human immunodeficiency virus-associated thrombotic microangiopathies: clinical characteristics and outcome according to ADAMTS13 activity. Scandinavian Journal of Immunology, 68, 337-344.
52. Mannucci, P.M., Canciani, M.T., Forza, I., Lussana, F., Lattuada, A. & Rossi, E. (2001) Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood, 98, 2730-2735.
53. Martin, M.G., Whitlatch, N.L., Shah, B. & Arepally, G.M. (2007) Thrombotic thrombocytopenic purpura induced by trimethoprim-sulfamethoxazole in a Jehovah's Witness. American Journal of Hematology, 82, 679-681.
54. Mazzei, C., Pepkowitz, S., Klapper, E. & Goldfinger, D. (1998) Treatment of thrombotic thrombocytopenic purpura: a role for early vincristine administration. Journal of Clinical Apheresis, 13, 20-22.
55. McCarthy, L.J., Porcu, P., Fausel, C.A., Sweeney, C.J. & Danielson, C.F. (1998) Thrombotic thrombocytopenic purpura and simvastatin. Lancet, 352, 1284-1285.
56. McDonald, V., Laffan, M., Benjamin, S., Bevan, D., Machin, S. & Scully, M.A. (2009) Thrombotic thrombocytopenic purpura precipitated by acute pancreatitis: a report of seven cases from a regional UK TTP registry. British Journal of Haematology, 144, 430-433.
57. McDonald, V., Manns, K., MacKie, I.J., Machin, S.J. & Scully, M.A. (2010) Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 8, 1201-1208.
58. Miller, D.P., Kaye, J.A., Shea, K., Ziyadeh, N., Cali, C., Black, C. & Walker, A.M. (2004) Incidence of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome. Epidemiology, 15, 208-215.
59. Miller, R.F., Scully, M., Cohen, H., Roedling, S., Starke, R., Edwards, S.G. & Machin, S.J. (2005) Thrombotic thrombocytopaenic purpura in HIV-infected patients. International Journal of STD and AIDS, 16, 538-542.
60. Mintz, P.D., Neff, A., Mackenzie, M., Goodnough, L.T., Hillyer, C., Kessler, C., McCrae, K., Menitove, J.E., Skikne, B.S., Damon, L., Lopez-Plaza, I., Rouault, C., Crookston, K.P., Benjamin, R.J., George, J., Lin, J.S., Corash, L. & Conlan, M.G. (2006) A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura. Transfusion, 46, 1693-1704.
61. Mokrzycki, M.H., Rickles, F.R., Kaplan, A.A. & Kohn, O.F. (1995) Thrombotic thrombocytopenic purpura in pregnancy: successful treatment with plasma exchange. Case report and review of the literature. Blood Purification, 13, 271-282.
62. Moore, J.C., Hayward, C.P., Warkentin, T.E. & Kelton, J.G. (2001) Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders. Blood, 98, 1842-1846.
63. Nguyen, L., Li, X., Duvall, D., Terrell, D.R., Vesely, S.K. & George, J.N. (2008) Twice-daily plasma exchange for patients with refractory thrombotic thrombocytopenic purpura: the experience of the Oklahoma Registry, 1989 through 2006. Transfusion, 48, 349-357.
64. O'Shaughnessy, D. (2006) Availability of imported fresh frozen plasma in England and North Wales. Department of Health Gateway reference 5999. URL:
65. O'Shaughnessy, D.F., Atterbury, C., Bolton, M.P., Murphy, M., Thomas, D., Yates, S. & Williamson, L.M. (2004) Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. British Journal of Haematology, 126, 11-28.
66. Pasquale, D., Vidhya, R., DaSilva, K., Tsan, M.F., Lansing, L. & Chikkappa, G. (1998) Chronic relapsing thrombotic thrombocytopenic purpura: role of therapy with cyclosporine. American Journal of Hematology, 57, 57-61.
67. Pereira, A., Mazzara, R., Monteagudo, J., Sanz, C., Puig, L., Martinez, A., Ordinas, A. & Castillo, R. (1995) Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: a multivariate analysis of factors predicting the response to plasma exchange. Annals of Hematology, 70, 319-323.
68. Peyvandi, F., Ferrari, S., Lavoretano, S., Canciani, M.T. & Mannucci, P.M. (2004) von Willebrand factor cleaving protease (ADAMTS-13) and ADAMTS-13 neutralizing autoantibodies in 100 patients with thrombotic thrombocytopenic purpura. British Journal of Haematology, 127, 433-439.
69. Peyvandi, F., Lavoretano, S., Palla, R., Feys, H.B., Vanhoorelbeke, K., Battaglioli, T., Valsecchi, C., Canciani, M.T., Fabris, F., Zver, S., Reti, M., Mikovic, D., Karimi, M., Giuffrida, G., Laurenti, L. & Mannucci, P.M. (2008) ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Haematologica, 93, 232-239.
70. Peyvandi, F., Palla, R., Lotta, L.A., Mackie, I., Scully, M.A. & Machin, S.J. (2010) ADAMTS-13 assays in thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 8, 631-640.
71. Pogliani, E.M., Perseghin, P., Parma, M., Pioltelli, P. & Corneo, G. (2000) Defibrotide in recurrent thrombotic thrombocytopenic purpura. Clinical and Applied Thrombosis/Hemostasis, 6, 69-70.
72. Ridolfi, R.L. & Bell, W.R. (1981) Thrombotic thrombocytopenic purpura. Report of 25 cases and review of the literature. Medicine (Baltimore), 60, 413-428.
73. Riedl, M., Rosales, A., Zimmerhackl, L.B. & Jungraithmayr, T. (2011) Actual and future strategies for transplantation in atypical HUS associated with mutations in factor H. Pediatric Transplantation, 15, 225-228.
74. Rio-Garma, J., Alvarez-Larran, A., Martinez, C., Muncunill, J., Castella, D., de la, R.J., Zamora, C., Corral, M., Viejo, A., Pena, F., Rodriguez-Vicente, P., Contreras, E., Arbona, C., Ramirez, C., Garcia-Erce, J.A., Alegre, A., Mateo, J. & Pereira, A. (2008) Methylene blue-photoinactivated plasma versus quarantine fresh frozen plasma in thrombotic thrombocytopenic purpura: a multicentric, prospective cohort study. British Journal of Haematology, 143, 39-45.
75. Rock, G.A., Shumak, K.H., Buskard, N.A., Blanchette, V.S., Kelton, J.G., Nair, R.C. & Spasoff, R.A. (1991) Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. New England Journal of Medicine, 325, 393-397.
76. Rock, G., Shumak, K.H., Sutton, D.M., Buskard, N.A. & Nair, R.C. (1996) Cryosupernatant as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Members of the Canadian Apheresis Group. British Journal of Haematology, 94, 383-386.
77. Rozdzinski, E., Hertenstein, B., Schmeiser, T., Seifried, E., Kurrle, E. & Heimpel, H. (1992) Thrombotic thrombocytopenic purpura in early pregnancy with maternal and fetal survival. Annals of Hematology, 64, 245-248.
78. Rutkow, I.M. (1978) Thrombotic thrombocytopenic purpura (TTP) and splenectomy: a current appraisal. Annals of Surgery, 188, 701-705.
79. Ruutu, T., Barosi, G., Benjamin, R.J., Clark, R.E., George, J.N., Gratwohl, A., Holler, E., Iacobelli, M., Kentouche, K., Lammle, B., Moake, J.L., Richardson, P., Socie, G., Zeigler, Z., Niederwieser, D. & Barbui, T. (2007) Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. Haematologica, 92, 95-100.
80. Sallee, M., Cretel, E., Jean, R., Chiche, L., Bourliere, M., Poullin, P., Lefevre, P. & Durand, J.M. (2008) Thrombotic thrombocytopenic purpura complicating interferon therapy in chronic C hepatitis. Gastroenterologie Clinique et Biologique, 32, 145-146.
81. Schiff, D.E., Roberts, W.D., Willert, J. & Tsai, H.M. (2004) Thrombocytopenia and severe hyperbilirubinemia in the neonatal period secondary to congenital thrombotic thrombocytopenic purpura and ADAMTS13 deficiency. Journal of Pediatric Hematology/oncology, 26, 535-538.
82. Schneppenheim, R., Budde, U., Oyen, F., Angerhaus, D., Aumann, V., Drewke, E., Hassenpflug, W., Haberle, J., Kentouche, K., Kohne, E., Kurnik, K., Mueller-Wiefel, D., Obser, T., Santer, R. & Sykora, K.W. (2003) von Willebrand factor cleaving protease and ADAMTS13 mutations in childhood TTP. Blood, 101, 1845-1850.
83. Scully, M., Gattens, M., Khair, K. & Liesner, R. (2006a) The use of intermediate purity factor VIII concentrate BPL 8Y as prophylaxis and treatment in congenital thrombotic thrombocytopenic purpura. British Journal of Haematology, 135, 101-104.
84. Scully, M., Starke, R., Lee, R., Mackie, I., Machin, S. & Cohen, H. (2006b) Successful management of pregnancy in women with a history of thrombotic thrombocytopaenic purpura. Blood Coagulation & Fibrinolysis, 17, 459-463.
85. Scully, M., Cohen, H., Cavenagh, J., Benjamin, S., Starke, R., Killick, S., Mackie, I. & Machin, S.J. (2007a) Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. British Journal of Haematology, 136, 451-461.
86. Scully, M., Longair, I., Flynn, M., Berryman, J. & Machin, S.J. (2007b) Cryosupernatant and solvent detergent fresh-frozen plasma (Octaplas) usage at a single centre in acute thrombotic thrombocytopenic purpura. Vox Sanguinis, 93, 154-158.
87. Scully, M., Yarranton, H., Liesner, R., Cavenagh, J., Hunt, B., Benjamin, S., Bevan, D., Mackie, I. & Machin, S. (2008) Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features. British Journal of Haematology, 142, 819-826.
88. Scully, M., McDonald, V., Cavenagh, J., Hunt, B.J., Longair, I., Cohen, H. & Machin, S.J. (2011) A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood, 118, 1746-1753.
89. Serrano, A., Xicoy, B., Grifols, J.R. & Ribera, J.M. (2007) [Thrombotic thrombocytopenic purpura during treatment with interpheron]. Medicina clínica (Barcelona), 128, 276-277.
90. Shumak, K.H., Rock, G.A. & Nair, R.C. (1995) Late relapses in patients successfully treated for thrombotic thrombocytopenic purpura. Canadian Apheresis Group. Annals of Internal Medicine, 122, 569-572.
91. Sundram, F., Roberts, P., Kennedy, B. & Pavord, S. (2004) Thrombotic thrombocytopenic purpura associated with statin treatment. Postgraduate Medical Journal, 80, 551-552.
92. Suzuki, M., Murata, M., Matsubara, Y., Uchida, T., Ishihara, H., Shibano, T., Ashida, S., Soejima, K., Okada, Y. & Ikeda, Y. (2004) Detection of von Willebrand factor-cleaving protease (ADAMTS-13) in human platelets. Biochemical and Biophysical Research Communications, 313, 212-216.
93. Taylor, C.M., Machin, S., Wigmore, S.J. & Goodship, T.H. (2010) Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom. British Journal of Haematology, 148, 37-47.
94. Terrell, D.R., Williams, L.A., Vesely, S.K., Lammle, B., Hovinga, J.A. & George, J.N. (2005) The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency. Journal of Thrombosis and Haemostasis, 3, 1432-1436.
95. Tsai, H.M. & Lian, E.C. (1998) Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. New England Journal of Medicine, 339, 1585-1594.
96. Tuncer, H.H., Oster, R.A., Huang, S.T. & Marques, M.B. (2007) Predictors of response and relapse in a cohort of adults with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: a single-institution experience. Transfusion, 47, 107-114.
97. Ucar, A., Fernandez, H.F., Byrnes, J.J., Lian, E.C. & Harrington, Jr, W.J. (1994) Thrombotic microangiopathy and retroviral infections: a 13-year experience. American Journal of Hematology, 45, 304-309.
98. Vesely, S.K., George, J.N., Lammle, B., Studt, J.D., Alberio, L., El Harake, M.A. & Raskob, G.E. (2003) ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood, 102, 60-68.
99. Vesely, S.K., Li, X., McMinn, J.R., Terrell, D.R. & George, J.N. (2004) Pregnancy outcomes after recovery from thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Transfusion, 44, 1149-1158.
100. Veyradier, A., Obert, B., Haddad, E., Cloarec, S., Nivet, H., Foulard, M., Lesure, F., Delattre, P., Lakhdari, M., Meyer, D., Girma, J.P. & Loirat, C. (2003) Severe deficiency of the specific von Willebrand factor-cleaving protease (ADAMTS 13) activity in a subgroup of children with atypical hemolytic uremic syndrome. Journal of Pediatrics, 142, 310-317.
101. Werner, T.L., Agarwal, N., Carney, H.M. & Rodgers, G.M. (2007) Management of cancer-associated thrombotic microangiopathy: what is the right approach? American Journal of Hematology, 82, 295-298.
102. Willis, M.S. & Bandarenko, N. (2005) Relapse of thrombotic thrombocytopenic purpura: is it a continuum of disease? Seminars in Thrombosis and Hemostasis, 31, 700-708.
103. Yarranton, H., Cohen, H., Pavord, S.R., Benjamin, S., Hagger, D. & Machin, S.J. (2003) Venous thromboembolism associated with the management of acute thrombotic thrombocytopenic purpura. British Journal of Haematology, 121, 778-785.
104. Yarranton, H., Lawrie, A.S., MacKie, I.J., Pinkoski, L., Corash, L. & Machin, S.J. (2005) Coagulation factor levels in cryosupernatant prepared from plasma treated with amotosalen hydrochloride (S-59) and ultraviolet A light. Transfusion, 45, 1453-1458.
105. Zakarija, A., Kwaan, H.C., Moake, J.L., Bandarenko, N., Pandey, D.K., McKoy, J.M., Yarnold, P.R., Raisch, D.W., Winters, J.L., Raife, T.J., Cursio, J.F., Luu, T.H., Richey, E.A., Fisher, M.J., Ortel, T.L., Tallman, M.S., Zheng, X.L., Matsumoto, M., Fujimura, Y. & Bennett, C.L. (2009) Ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic purpura (TTP): review of clinical, laboratory, epidemiological, and pharmacovigilance findings (1989-2008). Kidney International Supplement, 2, 0-S24.
106. Zheng, X.L., Kaufman, R.M., Goodnough, L.T. & Sadler, J.E. (2004) Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood, 103, 4043-4049.